Multiple studies demonstrate that melatonin exerts therapeutic antioxidant and anti-inflammatory effects in diabetes, mitigating complications such as oxidative stress, tissue damage, and inflammation.
The retrieved papers consistently provide experimental and clinical evidence showing that melatonin acts as a beneficial antioxidant and anti-inflammatory agent in diabetes models and patient populations, reducing oxidative stress markers and protecting against diabetes-associated organ damage. There are no papers refuting this claim.